European Journal of Clinical Pharmacology

, Volume 67, Issue 3, pp 283–288

Adverse events following immunization in children: retrospective analysis of spontaneous reports over a decade

  • Lise Aagaard
  • Erik Wind Hansen
  • Ebba Holme Hansen
Pharmacoepidemiology and Prescription



There is no doubt that paediatric immunization prevents serious diseases, but the administration of these vaccines to healthy children also involves risks of adverse drug reactions (ADRs), some of which are potentially serious. The current body of evidence on ADRs from immunization therapy at the population level is partly contradictory across countries, time periods and childhood immunization programmes. The objective of our study was to characterize reported adverse events (AEFIs) following immunization in Danish children.


Adverse events (AEFIs) in 0- to 17-year-old children and adolescents reported to the Danish Medicines Agency (DKMA) between 1998 and 2007 were analysed. The unit of analysis was one AEFI. Data were categorized with respect to time, age, and gender of the children, suspected vaccines, category and seriousness of the AEFIs, and reporting rate.


During the study period, the DKMA received 1,365 reports covering 2,600 AEFIs, corresponding to 60% of all adverse events reported for children. One third of the AEFIs were classified as serious, and two deaths were reported. The annual number of serious AEFIs remained constant during the study period. Approximately 80% of AEFIs were reported in children aged 0–2 years. Of all reported AEs, 45% were in the category “general disorders and administration site conditions”, followed by the categories “skin and subcutaneous tissue disorders” (20% of total AEFIs) and “nervous system disorders” (16% of total AEFIs). The largest share of serious events was from the category “nervous system disorders” (33% of serious AEFIs). The most frequently reported serious AEs were febrile convulsions, pyrexia, and injection-site reactions.


In Denmark, a large number of AEFIs following paediatric immunization have been reported, but the majority of cases were non-serious.


Children Vaccines Pharmacoepidemiology Immunization Denmark 


  1. 1.
    Letourneau M, Wells G, Walop W, Duclos P (2008) Improving global monitoring of vaccines safety. A survey of national centres participating in the WHO programme for international drug monitoring. Drug Saf 31:389–398CrossRefPubMedGoogle Scholar
  2. 2.
    Wendy E, Parmet JD (2010) Pandemic vaccines—the legal landscape. N Engl J Med 362:1949–1952CrossRefGoogle Scholar
  3. 3.
    O’Brien KK (2009) Pharmacists’ role in preventing vaccine-preventable diseases. US Pharm 34:39–45Google Scholar
  4. 4.
    Mrożek-Budzyn D, Kiełtyka A, Majewska R (2010) Lack of association between measles–mumps–rubella vaccination and autism in children: a case-control study. Pediatr Infect Dis J 29:397–400CrossRefPubMedGoogle Scholar
  5. 5.
    Madsen KM, Hviid A, Vestergaard M, Schendel D, Wohlfahrt J, Thorsen P, Olsen J, Melbye M (2002) A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med 347:1477–1482CrossRefPubMedGoogle Scholar
  6. 6.
    Hviid A, Stellfeld M, Wohlfahrt J, Melbye M (2004) Childhood vaccination and type 1 diabetes. N Engl J Med 350:1398–1404CrossRefPubMedGoogle Scholar
  7. 7.
    Hviid A, Melbye M (2008) Measles–mumps–rubella vaccination and asthma-like disease in early childhood. Am J Epidemiol 168:1277–1283CrossRefPubMedGoogle Scholar
  8. 8.
    Harris E (2010) After Wakefield: the real questions that needs addressing. Br Med J 340:c2829CrossRefGoogle Scholar
  9. 9.
    Jacobson RM (2003) Vaccine safety. Immunol Allergy Clin N Am 23:589–603CrossRefGoogle Scholar
  10. 10.
    Patja A, Davidkin I, Kurki T, Kallio MJ, Valle M, Peltola H (2000) Serious adverse events after measles–mumps–rubella vaccination during a fourteen-year prospective follow-up. Pediatr Infect Dis 19:1127–1134CrossRefGoogle Scholar
  11. 11.
    Mansoor O, Pillans PI (1997) Vaccine adverse events reported in New Zealand 1990–1995. NZ Med J 110:270–272Google Scholar
  12. 12.
    D’Souza RM, Campbell-Lloyd S, Isaacs D, Gold M, Burgess M, Turnbull F, O'Brien E (2000) Adverse events following immunisation associated with the 1998 Australian measles control campaign. Commun Dis Intell 24:27–33PubMedGoogle Scholar
  13. 13.
    Lawrence G, Menzies R, Burgess M, Wood N, Boyd I, Purcell P, Isaacs D (2003) Surveillance of adverse events following immunisation: Australia, 2000-2002. Commun Dis Intell 27:307–323PubMedGoogle Scholar
  14. 14.
    Lawrence G, Boyd I, McIntyre P, McIntyre P, Isaacs D (2004) Surveillance of adverse events following immunisation: Australia 2002 to 2003. Commun Dis Intell 28:324–338PubMedGoogle Scholar
  15. 15.
    Lawrence G, Boyd I (2005) Supplementary report: surveillance of adverse events following immunisation among children aged less than 7 years in Australia, 1 January to 30 June 2005. Commun Dis Intell 29:413–416PubMedGoogle Scholar
  16. 16.
    Lawrence GL, Aratchige PE, Boyd I, McIntyre PB, Gold MS (2007) Annual report on surveillance of adverse events following immunisation in Australia, 2006. Commun Dis Intell 31:269–282PubMedGoogle Scholar
  17. 17.
    Lawrence G, Gold MS, Hill R, Deeks S, Glasswell A, McIntyre B (2008) Annual report: surveillance of adverse events following immunisation in Australia, 2007. Commun Dis Intell 32:371–387PubMedGoogle Scholar
  18. 18.
    Aagaard L, Weber CB, Hansen EH (2010) Adverse drug reactions reported for children in Denmark from 1998–2007. Drug Saf 33:327–339CrossRefPubMedGoogle Scholar
  19. 19.
    Aagaard L, Hansen EH (2010) Adverse drug reactions from psychotropic medicines reported for children 1998–2007: a national register-based study from Denmark. BMC Res Notes 23(3):176CrossRefGoogle Scholar
  20. 20.
    Aagaard L, Hansen EH (2010) Adverse drug reactions reported for systemic antibacterials in Danish children over a decade. Br J Clin Pharmacol 70:765–768Google Scholar
  21. 21.
    The Danish National Board of Health. The children’s vaccination schedule in Denmark, 2009. Available at: ( Accessed 3 June 2010
  22. 22.
    Summary of product information. MFR vaccine. Available at: ( Accessed 3 June 2010
  23. 23.
    Summary of product information. Ditekipol/Act-Hib vaccine. Available at: ( Accessed 3 June 2010
  24. 24.
    Aagaard L, Stenver DI, Hansen EH (2008) Structures and processes in spontaneous reporting systems: a comparative study of Australia and Denmark. Pharm World Sci 30:563–570CrossRefPubMedGoogle Scholar
  25. 25.
    Roden S, Gibbs T (2007) CIOMS Working Groups and their contribution to pharmacovigilance. In: Mann RD, Andrews EB (eds) Pharmacovigilance, 2nd edn, chapter 23. John Wiley & Sons, Chichester, pp 287–305Google Scholar
  26. 26.
    MedDRA. Available at: (last accessed June 3 2010) [password required]
  27. 27.
    Pharmacovigilance: medicinal products for human use and veterinary products, vol. 9. Available at: Accessed 3 April 2010
  28. 28.
    Infomedia. Available at: Accessed 20 November 2009
  29. 29.
    Glissman S (2005) Danish Supreme Court rules that child with autism developed in temporal relation with MMR vaccination is not entitled to compensation. Euro Surveill 10:E050428.3Google Scholar
  30. 30.
    Hviid A, Stellfeld M, Wohlfahrt J, Andersen PH, Melbye M (2006) The impact of pre-school booster vaccination of 4–6-year-old children on pertussis in 0–1-year-old children. Vaccine 27:1401–1407CrossRefGoogle Scholar
  31. 31.
    Aagaard L, Hansen EH (2009) Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs and NSAIDs. BMC Clin Pharmacol 3(9):4CrossRefGoogle Scholar
  32. 32.
    Woo EJ, Ball R, Burwen DR, Braun MM (2008) Effects of stratification on data mining in the US Vaccine adverse event reporting system (VAERS). Drug Saf 31:667–674CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Lise Aagaard
    • 1
    • 3
  • Erik Wind Hansen
    • 2
  • Ebba Holme Hansen
    • 1
    • 3
  1. 1.Department of Pharmacology and Pharmacotherapy, Section for Social Pharmacy, Faculty of Pharmaceutical SciencesUniversity of CopenhagenCopenhagenDenmark
  2. 2.Department of Pharmacology and Pharmacotherapy, Section for Clinical Pharmacy, Faculty of Pharmaceutical SciencesUniversity of CopenhagenCopenhagenDenmark
  3. 3.FKL-Research Centre for Quality in Medicine Use, Faculty of Pharmaceutical SciencesUniversity of CopenhagenCopenhagenDenmark

Personalised recommendations